Opus, Viatris say presbyopia drug succeeds in Phase 3
Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year. The phentolamine ophthalmic solution 0.75% program ...
Opus Genetics and Viatris' eye drug hit the primary endpoint in a Phase 3 study, putting them on track for an FDA filing by the end of the year.
The phentolamine ophthalmic solution 0.75% program ...
